MG-132 - 10mM in DMSO , CAS No.1211877-36-9

CAS: 1211877-36-9 Cat. No.: M408577 Fórmula: C26H41N3O5 Peso molecular: 475.62
Disponible para pedir
CALIDAD & PUREZA 10mM in DMSO
Synonyms
Z-Leu-Leu-Leu-al
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Talla
USA
Alemania (EU)*
Precio
Cantidad
1ml
M408577-1ml
1 Disponible
—

228,90US$

266,90US$
Guardar 38,00 US$ (14.24%)
Enter a quantity for the sizes you want to add.

Descripción general

Information


In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

In vivo

Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA.
Cell Data

cell lines:N/TERT-1 keratinocytes

Concentrations:Dissolved in DMSO, final concentrations ~25 μM

Incubation Time:24 and 48 hours

Powder Purity:

Especificaciones

Sinónimos
Z-Leu-Leu-Leu-al
Especificaciones y pureza
10mM in DMSO
Mecanismos bioquímicos y fisiológicos
MG132 (Z-Leu-Leu-Leu-al) is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.
Condiciones de almacenamiento de almacenamiento
Store at -80°C
Enviado en
Dry ice packs + Cold packs
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Nombres e identificadores
Isómeros SMILES
CC(C)C[C@@H](C=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1
Peso molecular
475.62
Reaxys
11627647
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=11627647&ln=

Datos avanzados

Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Propiedades químicas y físicas
SolubilidadSolubility (25°C) In vitro DMSO: 100 mg/mL (122.85 mM); Ethanol: 100 mg/mL (122.85 mM); Water: Insoluble;
Seguridad y peligros (GHS)
Pictogramas
GHS07,   GHS09
Señal
Warning
Indicaciones de peligro

H227:Combustible liquid

H302:Harmful if swallowed

Precauciones

P210:Keep away from heat, hot surface, sparks, open flames and other ignition sources. - No smoking.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312:IF SWALLOWED: call a POISON CENTER/doctor/... IF you feel unwell.

P370+P378:In case of fire: Use ... to extinguish.

P403:Store in a well-ventilated place.

P501:Dispose of contents/container to an approved waste disposal plant.

Reaxys
11627647
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=11627647&ln=
Citations of This Product
Calculadoras de soluciones
Reseñas

Reseñas de cliente

Application Protocols

The following are general, literature-based protocols for using MG-132 in common research applications. Optimize for your specific system; this product is for research use only.

  1. Preparing stocks and working solutions
  • Dissolve compound in anhydrous DMSO to 10–50 mM.
  • Vortex briefly and, if needed, warm to room temperature to fully dissolve, then return to ice.
  • Sterile-filter (0.22 μm, low-protein-binding) if aseptic conditions are required.
  • Aliquot into light-protective tubes; store at −80°C.
  1. Cell-based proteasome inhibition (e.g., accumulation of ubiquitinated proteins)
  • Plate cells to reach 60–80% confluence on treatment day.
  • Prepare dosing media with final MG-132 concentrations of 0.5, 1, 2.5, 5, and 10 μM; keep DMSO constant (e.g., 0.1% v/v) across all wells, including vehicle control.
  • Incubate 4–8 h at 37°C, 5% CO2 (shorter or longer as needed).
  • Harvest cells; analyze by Western blot for polyubiquitin smears or specific substrates (e.g., IκBα stabilization).
  1. Fluorogenic proteasome activity assay (Suc-LLVY-AMC)
  • Prepare 20–50 μg/mL 20S proteasome or cell lysate in assay buffer (50 mM Tris pH 7.5, 1 mM EDTA).
  • Add substrate (50 μM) and MG-132 (0–1 μM) in a black 96-well plate.
  • Monitor fluorescence (Ex/Em 360/460 nm) at 25–37°C for 30–60 min; calculate initial rates and IC50.
  1. Washout kinetics (reversibility)
  • Treat cells with 5 μM MG-132 for 1 h; wash 3× with warm media; incubate in fresh media.
  • Sample at 0, 1, 2, 4 h post-wash to assess recovery of proteasome activity in lysates.

Always include vehicle controls and, when possible, an orthogonal inhibitor for mechanism verification.

Biological Roles

MG-132 is a research tool that modulates proteostasis by inhibiting the proteasome. The following describes its biological context based on literature; this product is for research use only.

  • Target/process:

    • Reversible inhibitor of the proteasome’s chymotrypsin-like (β5) catalytic activity within the 20S core (and thereby the 26S complex), via covalent but reversible adduct formation with Thr1.
  • Consequences of proteasome inhibition (cell biology):

    • Stabilization and accumulation of short-lived, ubiquitinated proteins.
    • Attenuation of IκBα degradation, reducing NF-κB transcriptional activation in many systems.
    • Activation of stress responses (e.g., UPR), increased polyubiquitin conjugates, and altered cell-cycle regulators.
  • Selectivity considerations:

    • At typical micromolar concentrations, MG-132 preferentially inhibits the chymotrypsin-like activity, with partial cross-inhibition of trypsin-like and caspase-like sites at higher doses (literature).
    • Off-target protease inhibition (e.g., calpains, cathepsins) can occur at higher concentrations; appropriate controls are recommended.
  • Experimental readouts:

    • Fluorogenic substrate assays (Suc-LLVY-AMC) show decreased cleavage rates.
    • Western blots reveal accumulation of ubiquitinated proteins and stabilization of proteasome substrates (e.g., p27, IκBα) depending on system.
  • Reversibility and kinetics:

    • Inhibition is rapidly established upon exposure and is reversible upon washout, with proteasomal activity gradually recovering (time scale dependent on dose and system).

No therapeutic or clinical use is implied; applications are confined to controlled laboratory studies.

Buffer Applications

This product is not a buffering reagent and is not used to prepare pH buffer systems. For experimental use, MG-132 is typically delivered to aqueous buffers via DMSO stock solutions. See “Solvent Selection,” “Application Protocols,” and “Storage & Reconstitution” for practical handling in biological media.

Green Alternatives

For MG-132 as a bioactive inhibitor, “green” considerations focus on solvent choice, exposure minimization, and potential substitution with agents of lower hazard while maintaining scientific objectives.

  • Solvent considerations (greener practice):

    • Prefer minimal DMSO percentages in assays (≤0.1% v/v) to reduce solvent burden.
    • When feasible, prepare intermediate dilutions in aqueous buffer immediately before use to limit DMSO waste.
    • Use microscale assay formats (96- to 384-well) to reduce chemical use and waste.
  • Alternative inhibitors (functional substitutions; literature):

    • Epoxyketones (e.g., carfilzomib/epoxomicin analogs) offer high specificity and irreversible binding; may allow lower working concentrations but can be more hazardous/reactive.
    • Boronate dipeptides (e.g., bortezomib/ixazomib analogs) provide potent inhibition with different reactivity; handling and disposal must follow strict controls.
    • Peptide aldehydes with altered sequences (e.g., MG-115, MG-262) can tune selectivity profiles; choose the minimal potency needed for the study to limit exposure.
  • Trade-offs:

    • More potent/irreversible inhibitors may enable lower dosing (less mass used) but can increase persistence/reactivity hazards.
    • MG-132’s reversibility facilitates washout and temporal control, potentially reducing prolonged exposure.
  • Operational green tips:

    • Aliquot to avoid freeze–thaw waste; adopt just-in-time thawing.
    • Implement sorbent-based capture for DMSO/organic waste where permitted.
    • Document and benchmark inhibitor and solvent use to drive continuous reduction without compromising data quality.
Pharmaceutical Uses

MG-132 is supplied strictly for research use only. It is not an excipient and has no pharmacopeial monograph as a formulation aid.

  • Research/formulation context (general):

    • In vitro tools: Used in cell and biochemical assays to transiently inhibit proteasome function.
    • Not intended for human or veterinary administration. No clinical or therapeutic claims are made or implied.
  • Manufacturing/analytical context:

    • May serve as a system-suitability or positive-control compound for proteasome activity assays in drug discovery workflows.
    • For any regulated work, verify identity, purity, and stability using your internal QC procedures and the provided CoA.
Physical Properties

Item-specific values were not provided in the Product Data. The following are general/literature characteristics for MG-132; verify details for this specific SKU on the CoA/Spec Sheet.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight (literature): ~475.62 g/mol (MG-132 free base/neutral form)
  • Molecular formula (literature): C26H41N3O5
  • Physical state: Typically supplied as a solid; often off-white to white (literature, varies by lot and form/salt).
  • Melting point: Not specified for this item; literature reports vary depending on form.
  • Boiling point: Not applicable (decomposes before boiling; peptide-like compound).
  • Solubility (literature, practical lab guidance):
    • DMSO: Readily soluble; stocks commonly prepared at 10–50 mM.
    • Ethanol: Soluble at lower millimolar concentrations.
    • Aqueous buffers: Limited solubility; typically delivered to aqueous media via DMSO carrier (final DMSO ≤0.1–0.5% v/v is common practice).
  • LogP/logD: Not widely reported; the compound is relatively lipophilic due to three leucine side chains and CBZ group (qualitative, literature-based).
  • pKa: No titratable groups in the physiological range; behaves as a neutral peptide-aldehyde under assay conditions (literature, qualitative).
  • Refractive index, UV cutoff, residuals/impurities: Not specified for this item; refer to CoA/Spec Sheet.
Quality and Grades
  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

  • What grade implies (general guidance):

    • For small-molecule bioactives such as MG-132, vendors typically specify purity by HPLC (>95% or similar), with supporting LC/MS and/or NMR identity confirmation. Low levels of related peptide impurities and oxidation products are important quality considerations.
    • Residual solvents, water content, and counter-ions (if salt forms are supplied) may be reported. For proteasome inhibitors, the active aldehyde content is functionally critical.
  • Stabilizers: None specified for this item; if present in specific lots, stabilizers (e.g., small amounts of antioxidants) would be disclosed on the CoA. Any stabilizer can influence biological assays and should be considered in dose-response interpretation.

  • What to check on receipt:

    • Verify CAS/form match between label and CoA (MG-132 appears in literature under multiple identifiers; ensure the SKU corresponds to the intended form).
    • Review HPLC trace for single dominant peak, expected retention, and absence of late-eluting hydrophobic impurities.
    • Confirm identity by MS (m/z consistent with the neutral/plus adducts) and, if needed, by 1H NMR in DMSO-d6.
  • Suitability for intended use:

    • For cell biology, purity and low endotoxin/bioburden (if reported) are desirable. For biochemical assays, ensure absence of interfering UV-absorbing impurities that could affect readouts.
Reaction and Applications

This product is primarily a biological tool compound rather than a synthetic reagent. Its core application is reversible inhibition of the proteasome.

  • Biological assay applications (literature/general):

    • Inhibits the chymotrypsin-like (β5) activity of the 20S/26S proteasome by forming a reversible hemiacetal/hemithioacetal with the N-terminal Thr1 of the catalytic subunit.
    • Commonly used to block proteasomal degradation in studies of the ubiquitin–proteasome system (UPS), protein quality control, and regulated protein turnover.
    • Employed to modulate NF-κB signaling by preventing IκBα degradation (monitor IκBα accumulation as a pharmacodynamic readout).
    • Used to induce proteotoxic stress and study unfolded protein response (UPR), autophagy crosstalk, and aggresome formation.
  • Experimental use cases:

    • Cell-based: Short (2–24 h) treatments at 0.5–10 μM; confirm cell line–specific sensitivity and include viability controls.
    • Biochemical: Proteasome activity assays using fluorogenic substrates (e.g., Suc-LLVY-AMC) where MG-132 serves as a reference inhibitor.
  • Practical notes:

    • Light and moisture can degrade peptide aldehydes; prepare fresh working solutions and minimize exposure.
    • Include vehicle (DMSO) controls and, where relevant, orthogonal inhibitors (e.g., epoxyketones) for mechanism confirmation.
    • Washout experiments can demonstrate reversibility and kinetics of proteasome recovery.
  • Not typically used in organic synthesis; see “Synthetic Utility” for limited roles as a reference standard.

Reaction Conditions

As a biological inhibitor rather than a synthetic reagent, “reaction conditions” pertain to inhibition assays and cell-based exposures. The following ranges are compiled from literature and common laboratory practice; optimize for your system.

  • Stock preparation:

    • Dissolve in anhydrous DMSO at 10–50 mM. Prepare single-use aliquots and store at −80°C.
  • Biochemical proteasome assays (literature/general):

    • Assay buffer: 20–50 mM Tris or HEPES, pH 7.4–8.0, 0.5–1 mM EDTA, 0.03–0.1% NP-40/Triton X-100 optional.
    • Substrate: Suc-LLVY-AMC (chymotrypsin-like activity), 10–100 μM.
    • MG-132: 50–500 nM to low μM for partial to near-complete inhibition.
    • Temperature: 25–37°C; monitor AMC fluorescence over 5–60 min.
  • Cell-based studies (literature/general):

    • Working concentration: 0.5–10 μM for 2–24 h. Short pulses (30–120 min) are used for reversible inhibition/washout experiments.
    • Vehicle: DMSO at ≤0.1–0.5% v/v final; include vehicle control.
    • Readouts: Western blot for ubiquitinated proteins, proteasome activity in lysates, reporter assays (e.g., NF-κB).
  • Compatibility:

    • Serum-containing media are generally compatible; adsorption to plastics can occur—use low-binding labware when dosing at sub-μM levels.
  • Notes:

    • Cytotoxicity increases with dose/time; include viability assays (e.g., CellTiter, Trypan Blue) to contextualize data.
    • Protect solutions from light and moisture; prepare fresh working dilutions immediately before use.
Safety and Handling
  • GHS information for this catalog item:

    • Signal word: Not specified for this item; refer to SDS.
    • Hazard statements (H-phrases): Not specified for this item; refer to SDS.
    • GHS pictograms/classification: Not specified for this item; refer to SDS.
  • General safety profile (literature/typical for peptide aldehydes):

    • May cause skin/eye irritation and respiratory irritation; handle in a chemical fume hood.
    • Avoid inhalation, ingestion, and contact with skin/eyes. Wear appropriate PPE (lab coat, nitrile gloves, safety glasses or face shield).
    • Aldehyde functionality may react with amines/thiols; avoid contact with amino-containing reagents or surfaces when handling concentrated solutions.
  • Handling practices:

    • Work quickly on ice when preparing solutions to minimize hydrolysis/oxidation of the aldehyde.
    • Use dry, oxygen- and moisture-minimized techniques for weighing and dissolving. Close caps promptly.
    • Prepare single-use aliquots to avoid repeated freeze–thaw.
  • Incompatibilities (general): Strong oxidizers; strong bases/acids that can promote degradation; nucleophiles that can add to the aldehyde.

  • First aid (general guidance; defer to SDS):

    • Skin/eye contact: Rinse cautiously with water for several minutes; remove contaminated clothing; seek medical advice if irritation persists.
    • Inhalation: Move to fresh air; seek medical attention if symptoms develop.
    • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
  • Waste: Collect unused solutions and contaminated disposables as organic hazardous waste per institutional and local regulations.

  • For research use only; not for human or veterinary use.

Solvent Selection

MG-132 is a lipophilic peptide-aldehyde and is typically handled as DMSO stocks for biological assays.

  • Polarity/miscibility (literature/general):

    • DMSO: Excellent solvent; supports 10–50 mM stocks.
    • Ethanol: Good solubility; use fresh to avoid acetaldehyde/impurity reactions.
    • DMF: Good solubility; consider toxicity and handling.
    • Water/buffers: Poor intrinsic solubility; deliver via DMSO cosolvent. Surfactants (0.01–0.1% Tween-20) can aid dispersion in some assays.
  • Practical selection tips:

    • Default choice: Anhydrous DMSO for concentrated master stocks; filter-sterilize if required using low-protein-binding membranes.
    • For in vitro enzymology where DMSO must be minimized, pre-dilute DMSO stock into buffer to ≤0.1% v/v final; include DMSO vehicle controls.
    • Avoid strong nucleophilic solvents (e.g., primary amines) that could react with the aldehyde.
  • Small comparison (general):

    • DMSO: Highest solvency, biologically tolerated at low %; hygroscopic.
    • Ethanol: Volatile, easier to remove; may affect cell membranes at ≥0.5–1%.
    • Aqueous: Requires cosolvent; limits compound precipitation.
  • Degassing/drying: Use dry solvent to limit aldehyde hydration; work quickly, protect from moisture and air when feasible.

Storage and Reconstitution
  • Storage conditions (item-specific from Product Data):

    • Store at −80°C.
    • Shipped on dry ice packs + cold packs to maintain low temperature.
  • Stability (general/literature guidance for peptide aldehydes):

    • Solid form: More stable when kept desiccated, sealed, and protected from light at ≤−20°C; −80°C is preferred for long-term storage.
    • Solutions: DMSO stocks are stable for weeks to months at −80°C if moisture- and light-protected; avoid repeated freeze–thaw cycles.
  • Reconstitution (general practice):

    • Bring vial to room temperature in a desiccated environment before opening to prevent condensation.
    • Dissolve the solid in anhydrous DMSO to prepare a 10–50 mM stock. Mix gently until homogeneous.
    • Optional: Sonicate briefly or warm slightly (≤30°C) to aid dissolution, then return to ice.
    • Aliquot into single-use portions (e.g., 10–50 μL) in low-bind, amber tubes; flush headspace with inert gas if available.
  • Working solutions:

    • Prepare immediately before use by diluting the DMSO stock into pre-warmed medium or assay buffer. Keep final DMSO content consistent across samples (commonly ≤0.1–0.5% v/v).
    • Discard any unused diluted solutions; do not refreeze dilute aqueous mixtures.
  • Additional notes:

    • Avoid exposure to moisture, strong light, and reactive nucleophiles.
    • Label aliquots with concentration, date, and freeze–thaw count for traceability.
  • Research Use Note: For research use only.

Structure and Identity

MG-132 is a peptide aldehyde proteasome inhibitor widely used as a tool compound to block the ubiquitin–proteasome system in cells.

  • Item-specific identifiers from Product Data:

    • SKU: M408577
    • CAS: 1211877-36-9 (note: MG-132 is commonly known in literature under other CAS numbers; verify against the CoA for this specific lot/form)
    • Category: Small molecules and compound libraries (小分子和化合物库)
  • Structure (general/literature description):

    • Common name: MG-132; also described as Z-Leu-Leu-Leu-al (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal)
    • Structural features: N-terminal benzyloxycarbonyl (Z/CBZ) protecting group; tripeptidic backbone of L-Leu–L-Leu–L-Leu; C-terminal aldehyde (–CHO), which forms a reversible covalent adduct with the N-terminal threonine of the proteasome active site.
    • Functional groups: carbamate (CBZ), amide bonds (peptidic), aliphatic isobutyl side chains (leucines), terminal aldehyde.
    • Stereochemistry: typically all-L configuration at the three leucine residues (literature), giving a chiral, conformationally flexible peptide-like small molecule.
  • Computed/literature identifiers (for general reference; confirm for this catalog item):

    • Molecular formula (literature): C26H41N3O5
    • Molecular weight (literature): ~475.62 g/mol
    • SMILES/InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
  • 2D structural description in words: A CBZ-protected N-terminus linked via two amide bonds to a tripeptide of leucines, terminating in an aldehyde; an overall lipophilic peptide-aldehyde scaffold.

Synthetic Utility

MG-132 is not commonly employed as a general-purpose synthetic building block due to its peptide-aldehyde functionality and specialized bioactivity. However, in certain research settings, it has limited utility:

  • Reference standard: Serves as a qualitative/quantitative standard in LC–MS or HPLC method development for peptide-like proteasome inhibitors.
  • Reactivity considerations (general):
    • The terminal aldehyde can form imines/hemiacetals with nucleophiles; this underlies its biological activity but also leads to potential side reactions in synthetic contexts.
    • The CBZ group and amide bonds are stable under mild conditions but can be hydrogenolyzed (CBZ) or hydrolyzed under strong acidic/basic conditions (general peptide chemistry).
  • Derivatization (advanced, literature):
    • Modifying the N-terminus (alternative protecting groups) or C-terminus (aldehyde to alcohol/acid/oxime) provides SAR probes for proteasome subsite mapping.
    • Isotopically labeled MG-132 analogs can be prepared for tracer studies or internal standards.

Given its cost and instability relative to simpler building blocks, MG-132 is best treated as a finished tool compound rather than a substrate for multistep synthesis.

Target Specificity

No item-specific target validation data were provided in the Product Data. The following reflects literature knowledge for MG-132 as a class representative; confirm performance in your system.

  • Primary target: 20S/26S proteasome, β5 (PSMB5) chymotrypsin-like catalytic site (Thr1-dependent mechanism) via reversible covalent adduct formation.

  • Selectivity profile (literature/general):

    • Chymotrypsin-like site: High potency (reported biochemical IC50 often in the ~0.1–1 μM range depending on assay format and enzyme source).
    • Trypsin-like (β2) and caspase-like (β1) sites: Inhibited at higher concentrations (reduced potency relative to β5).
    • Off-targets: At ≥ low micromolar concentrations, inhibition of certain cysteine proteases (e.g., calpains, cathepsins) has been reported; use orthogonal probes to confirm on-target effects.
  • Binding mode: Reversible covalent inhibition through the aldehyde reacting with the N-terminal threonine of the catalytic subunit; peptide backbone engages specificity pockets (S1–S3) favoring hydrophobic residues.

  • Cellular specificity considerations:

    • Cellular uptake is adequate for many mammalian lines; potency can vary with efflux transporter expression and proteasome load.

All values above are literature-general and not specifications for this catalog item.

Preguntas frecuentes

How should this product be stored?
Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1211877-36-9, the molecular formula is C26H41N3O5, and the molecular weight is 475.62 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

¿Quieres que te enviemos un mensaje cuando tengamos descuentos disponibles?

Recordármelo más tarde

¡Gracias! Por favor, revisa tu bandeja de entrada de correo electrónico para confirmar.

¡Vaya! Las notificaciones están desactivadas.